Wilate 500 500 IU VWF500 IU FVIII Powder and Solvent for Solution for Injection

Krajina: Malajzia

Jazyk: angličtina

Zdroj: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Kúpte ho teraz

Stiahnuť Príbalový leták (PIL)
29-11-2020

Aktívna zložka:

coagulation factor VIII; Von Willebrand Factor

Dostupné z:

Pharmaniaga Marketing Sdn Bhd

INN (Medzinárodný Name):

coagulation factor VIII; Von Willebrand Factor

Počet v balení:

1vial Vials

Výrobca:

OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES.M.B.H.

Príbalový leták

                                Not Applicable
                                
                                Prečítajte si celý dokument
                                
                            

Súhrn charakteristických

                                XXXXXXX-XX
XXXXXXX-XX
XXXXXXX-XX
Mat-No./CAN/DataMatrix: XXXXXXX-XX (CODE IS A SAMPLE) / Version: 09 /
2020-09-28 / Product code: 189 / WILATE / MALAYSIA / 520 X 270 MM /
BLACK / SATZSTUDIO BORNGRÄBER / font size: 9PT
INSTRUCTION FOR USE
(SUMMARY OF PRODUCT CHARACTERISTICS)
1 NAME OF THE MEDICINAL PRODUCT
WILATE 500, 500 IU VWF/500 IU FVIII, powder and
solvent for solution for injection
WILATE 1000, 1000 IU VWF/1000 IU FVIII, powder and
solvent for solution for injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Wilate is presented as a powder and solvent for solution for
injection.
Each vial contains nominally 500 IU/1000 IU human von Willebrand
factor (VWF
)
and human coagulation factor VIII (FVIII).
The product contains approximately 100 IU/ml human von Willebrand
factor when reconstituted with 5 ml/10 ml Water for Injections with
0.1 % Polysorbate 80.
The specific activity of Wilate is ≥ 67 IU VWF:RCo/mg protein.
The VWF potency (IU) is measured according to ristocetin cofactor
activity (VWF:RCo) compared to the International Standard for von
Willebrand Factor Concentrate (WHO).
The product contains approximately 100 IU/ml human coagulation
factor VIII when reconstituted with 5 ml/10 ml Water for Injections
with 0.1% Polysorbate 80.
The potency (IU) is determined using the European Pharmacopoeia
chromogenic assay. The specific activity of Wilate is ≥ 67 IU
FVIII:C/
mg protein.
Produced from the plasma of human donors.
Excipient(s) with known effect:
Wilate 500: 11.7 mg sodium per ml reconstituted solution (58.7 mg
sodium per vial).
Wilate 1000: 11.7 mg sodium per ml reconstituted
solution (117.3 mg per vial).
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Powder and solvent for solution for injection.
Freeze-dried powder: white or pale yellow powder or crumbly solid.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Von Willebrand disease (VWD)
Prevention and treatment of haemorrhage or surgical bleeding
in von Willebrand disease (VWD), when desmopressin (DDAVP)
treatment alone
                                
                                Prečítajte si celý dokument
                                
                            

Vyhľadávajte upozornenia súvisiace s týmto produktom